Document:

Exhibit
10.8

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of November 4, 2021, between Naked Brand Group Limited,
an Australian corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

 

WHEREAS,
the Company and Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
by the Securities Act (as defined below) and the Company’s agreement to register for resale under the Securities Act the securities
sold hereby; and

 

WHEREAS,
subject to the terms and conditions set forth in this Agreement, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

 

NOW,
THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

 

ARTICLE
I.

DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:

 

“Acquiring
Person” shall have the meaning ascribed to such term in Section 4.4.

 

“Action”
shall have the meaning ascribed to such term in Section 3.1(j).

 

“Affiliate”
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

 

“Australian
Counsel” means Mills Oakley.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Combination” means the consolidation, merger, spin-off, corporate reorganization or any other similar transaction involving
the Company and Cenntro Automotive Group Limited, a Cayman Island company limited by shares, in which the Company shall be the surviving
entity.

 

“Business
Day” means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to “stay at home”, “shelter-in-place”, “non-essential employee”
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally
are open for use by customers on such day.

 

“Closing”
means the closing of the purchase and sale of the Units pursuant to Section 2.1.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s
obligations to deliver the Units, in each case, have been satisfied or waived, but in no event later than the first (1st)
Trading Day following the date hereof.

 

    	 

     

    

 

“Commission”
means the United States Securities and Exchange Commission.

 

“Company
Counsel” means Graubard Miller, with offices located at 405 Lexington Ave, 11th Floor, New York, NY 10174.

 

“Disclosure
Time” means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the
date hereof, unless otherwise instructed as to an earlier time by the Purchasers, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date
hereof, unless otherwise instructed as to an earlier time by the Purchasers.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“Exempt
Issuance” means the issuance of (a) Ordinary Shares or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) Ordinary
Shares upon the exercise or exchange of securities exercisable or exchangeable for or convertible into Ordinary Shares issued and outstanding
on the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number
of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection
with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, provided that any such issuance shall only be to a
Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset
in a business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment
of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital
or to an entity whose primary business is investing in securities.

 

“Extraordinary
General Meeting” means Extraordinary General Meeting of the Company’s shareholders held for the purpose of approving
the Business Combination.

 

“FCPA”
means the Foreign Corrupt Practices Act of 1977, as amended.

 

“Five-Year
Warrant” means a warrant, in the form attached hereto as Exhibit A, where each whole warrant entitles the holder to
purchase one Ordinary Share, provided that such warrant shall have an Expiration Date (as defined therein) that is the earlier of: (i)
one year from the Issuance Date (as defined therein) or (ii) the date that the Business Combination is completed.

 

“IFRS”
shall have the meaning ascribed to such term in Section 3.1(h).

 

“Indebtedness”
shall have the meaning ascribed to such term in Section 3.1(aa).

 

“Intellectual
Property Rights” shall have the meaning ascribed to such term in Section 3.1(p).

 

“Liens”
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

 

“Material
Adverse Effect” means: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company and the Subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company’s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document; provided, however, that “Material Adverse Effect”
does not mean or include any condition, event, or change which (x) results from events or occurrences relating to the global economy
in general, (y) acts of war, sabotage, terrorism, natural or man-made disasters, epidemics, pandemics (including COVID-19), acts of God,
and measures taken by governments, or political or administrative subdivisions thereof, in response thereto, (z) changes in the Company’s
industry in general and not having a disproportionate impact on the Company

 

    	 

     

    

 

“Material
Permits” shall have the meaning ascribed to such term in Section 3.1(n).

 

“MWE”
means McDermott Will and Emery LLP, with offices located at One Vanderbilt Avenue New York, NY 10017-3852.

 

“One-Year
Warrant” means a warrant, in the form attached hereto as Exhibit A, where each whole warrant entitles the holder to
purchase one Ordinary Share, provided that such warrant shall have an Expiration Date (as defined therein) that is the earlier of: (i)
one year from the Issuance Date (as defined therein) or (ii) the date that the Business Combination is completed.

 

“Ordinary
Shares” means the ordinary shares of the Company, no par value per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.

 

“Ordinary
Share Equivalents” means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Ordinary Shares, including, without limitation, any debt, preferred share, right, option, warrant or other instrument that
is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Ordinary Shares.

 

“Per
Unit Purchase Price” equals $0.6012, subject to adjustment for reverse and forward share splits, share dividends, share combinations
and other similar transactions of the Ordinary Shares that occur after the date of this Agreement and prior to the Closing Date.

 

“Person”
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint share company, government (or an agency or subdivision thereof) or other entity of any kind.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Prospectus”
means the prospectus supplement to the Registration Statement, which offers for resale the Ordinary Shares underlying the Units sold
to the Purchasers (including the Warrant Shares, in an amount equal to 150% of the number of Warrant Shares initially issuable upon cash
exercise of the Warrants).

 

“Purchaser
Party” shall have the meaning ascribed to such term in Section 4.7.

 

“Registration
Statement” means the automatic shelf registration statement on Form F-3 (File No. 333-256258), including all information, documents
and exhibits filed with or incorporated by reference into such registration statement.

 

“Required
Approvals” shall have the meaning ascribed to such term in Section 3.1(e).

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.

 

“Rule
424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.

 

    	 

     

    

 

“SEC
Reports” shall have the meaning ascribed to such term in Section 3.1(h).

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing Ordinary Shares).

 

“Subscription
Amount” means, as to each Purchaser, the aggregate amount to be paid for Units purchased hereunder as specified below such
Purchaser’s name on the signature page of this Agreement and next to the heading “Subscription Amount,” in United States
dollars and in immediately available funds.

 

“Subsidiary”
means any subsidiary of the Company as set forth in the SEC Reports, and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.

 

“Trading
Day” means a day on which the principal Trading Market is open for trading.

 

“Trading
Market” means any of the following markets or exchanges on which the Ordinary Shares are listed or quoted for trading on the
date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New
York Stock Exchange (or any successors to any of the foregoing).

 

“Transaction
Documents” means this Agreement, all exhibits and schedules hereto and any other documents or agreements executed in connection
with the transactions contemplated hereunder.

 

“Transfer
Agent” means Continental Stock Transfer & Trust Company.

 

“Units”
means the Units, each containing one Ordinary Share, one Five-Year Warrant and sixty-five hundredths (65/100) of one One-Year Warrant,
issued or issuable to each Purchaser pursuant to this Agreement.

 

“Warrant”
means the Five-Year Warrant and/or the One-Year Warrant, as applicable.

 

“Warrant
Shares” means the Ordinary Shares issuable upon the exercise of the Warrants.

 

ARTICLE
II.

PURCHASE AND SALE

 

2.1
Closing. On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the
execution and delivery of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly,
agree to purchase, up to an aggregate of $30,000,000 of Units. The Company shall deliver to each Purchaser its respective Units upon
the Company’s receipt of payment therefor, and the Company and each Purchaser shall deliver the other items set forth in Section
2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall
occur at the offices of MWE or such other location as the parties shall mutually agree. Notwithstanding anything to the contrary herein
and the Purchaser’s Subscription Amount set forth on the signature pages attached hereto, the number of Ordinary Shares purchased
by a Purchaser (and its Affiliates) hereunder (including the Ordinary Shares underlying the Units and the Warrant Shares) shall not,
when aggregated with all other Ordinary Shares owned by such Purchaser (and its Affiliates) at such time, result in such Purchaser beneficially
owning (as determined in accordance with Section 13(d) of the Exchange Act) in excess of 9.9% of the then issued and outstanding Ordinary
Shares outstanding at the Closing (the “Beneficial Ownership Maximum”). To the extent that a Purchaser’s beneficial
ownership of the Ordinary Shares would otherwise be deemed to exceed the Beneficial Ownership Maximum, such Purchasers’ Subscription
Amount shall automatically be reduced as necessary in order to comply with this paragraph.

 

    	 

     

    

 

2.2
Deliveries.

 

(a)
On or prior to the Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the
following:

 

(i)
this Agreement duly executed by the Company;

 

(ii)
a legal opinion of Company Counsel, in form and substance reasonably acceptable to the Purchasers;

 

(iii)
a legal opinion of Australian Counsel, in form and substance reasonably acceptable to the Purchasers;

 

(iv)
a secretary’s certificate, in form and substance reasonably acceptable to the Purchasers;

 

(v)
an officer’s certificate, in form and substance reasonably acceptable to the Purchasers;

 

(vi)
subject to the last sentence of Section 2.1, the Company shall have provided the Purchasers with the Company’s wire instructions,
on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer;

 

(vii)
subject to the last sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent
to deliver on an expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (“DWAC”)
Units equal to such Purchaser’s Subscription Amount divided by the Per Unit Purchase Price, registered in the name of such Purchaser
(provided, that any fractional units resulting from such quotient and the Subscription Amount applicable thereto shall be disregarded
and the total number of Units issuable to the Purchaser shall be rounded down to the nearest whole number of Units); and

 

(viii)
the form of the Prospectus, which shall be filed with the Commission promptly after Closing.

 

(b)
On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, as applicable, the following:

 

(i)
this Agreement duly executed by such Purchaser; and

 

(ii)
such Purchaser’s Subscription Amount, under which the Purchaser shall on the Closing Date, deliver via wire transfer immediately
available funds to the Company or its designee.

 

2.3
Closing Conditions.

 

(a)
The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a
specific date therein in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been
performed;

 

(iii)
the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement; and

 

    	 

     

    

 

(iv)
Nasdaq shall have completed its review of the Nasdaq Notice and shall not have raised an objection to the transactions contemplated hereby.

 

(b)
The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:

 

(i)
the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse
Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless
as of a specific date therein in which case they shall be accurate as of such date);

 

(ii)
all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;

 

(iii)
the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;

 

(iv)
there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and

 

(v)
from the date hereof to the Closing Date, trading in the Ordinary Shares shall not have been suspended by the Commission or the Company’s
principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such
magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of
such Purchaser, makes it impracticable or inadvisable to purchase the Units at the Closing; and

 

(vi)
Nasdaq shall have completed its review of the Nasdaq Notice and shall not have raised an objection to the transactions contemplated hereby.

 

ARTICLE
III.

REPRESENTATIONS AND WARRANTIES

 

3.1
Representations and Warranties of the Company. Except as set forth in the SEC Reports, the Company hereby makes the following
representations and warranties to each Purchaser:

 

(a)
Subsidiaries. All of the direct and indirect significant subsidiaries of the Company are set forth in the SEC Reports. Except
as set forth in the SEC Reports, the Company owns, directly or indirectly, all of the capital stock or other equity interests of each
Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each Subsidiary are validly
issued and are fully paid, non-assessable and free of preemptive and similar rights to subscribe for or purchase securities. If the Company
has no subsidiaries, all other references to the Subsidiaries or any of them in the Transaction Documents shall be disregarded.

 

(b)
Organization and Qualification. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing (if the concept of good standing exists in such jurisdiction) under the laws of the jurisdiction
of its incorporation or organization, with the requisite power and authority to own and use its properties and assets and to carry on
its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its
respective constitution, certificate or articles of incorporation, bylaws or other organizational or charter documents. Each of the Company
and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction
in which the nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to
be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in a Material Adverse Effect
and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail
such power and authority or qualification.

 

    	 

     

    

 

(c)
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder.
The execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of
the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no
further action is required by the Company, the Board of Directors or the Company’s shareholders in connection herewith or therewith
other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been
(or upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will
constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as
limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.

 

(d)
No Conflicts. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to
which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby
do not and will not (i) conflict with or violate any provision of the Company’s or any Subsidiary’s constitution, certificate
or articles of incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or
an event that with notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the
properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or
other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary
is a party or by which any property or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required
Approvals, conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction
of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and
regulations), or by which any property or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses
(ii) and (iii), such as could not have or reasonably be expected to result in a Material Adverse Effect.

 

(e)
Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other
Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings
required pursuant to Section 4.3 of this Agreement, (ii) the filing with the Commission of the Registration Statement and the Prospectus,
(iii) the filing of the listing of additional shares notice with Nasdaq for the listing of the Ordinary Shares underlying the Units and
the Warrant Shares for trading thereon (the “Nasdaq Notice”), or such other notice(s) to such Trading Markets, as
applicable, in the time and manner required thereby (or as promptly as practicable) and (iv) such filings as are required to be made
under applicable state securities laws (collectively, the “Required Approvals”). On or prior to the date hereof, the
Company has submitted the Nasdaq Notice.

 

    	 

     

    

 

(f)
Issuance of the Units; Registration. The Ordinary Shares included in the Units are duly authorized and, when issued and paid for
in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear
of all Liens imposed by the Company. The issuance of the Warrants included in the Units pursuant to the Transaction Documents is duly
authorized, and upon the due execution, issuance and delivery thereof against payment in full therefor in accordance with the terms of
this Agreement, the Warrants will be valid and binding obligations of the Company enforceable against the Company in accordance with
their terms (except (i) as may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors’ rights
generally, (ii) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws, and (iii) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefor may be brought). The issuance of the Ordinary Shares
issuable upon exercise of the Warrants is duly authorized, and upon issuance and against payment therefor in accordance with the Warrants,
such Ordinary Shares will be validly issued, fully paid and non-assessable, free and clear of all Liens imposed by the Company. The Company
has reserved from its duly authorized capital stock the maximum number of Ordinary Shares issuable pursuant to this Agreement. The Company
has prepared the Registration Statement, including the Prospectus, in conformity with the requirements of the Securities Act. At the
time of filing of the Registration Statement, the Company was eligible to use Form F-3 under the Securities Act and met the transaction
requirements as set forth in General Instruction I.B.1 of Form F-3.

 

(g)
Capitalization. The capitalization of the Company as of the date hereof is as set forth in the SEC Reports. The Company has not
issued any capital stock since its most recently periodic report filed under the Exchange Act or its most recent report furnished on
Form 6-K under the Exchange Act, other than pursuant to the exercise of employee share options under the Company’s share option
plans, the issuance of Ordinary Shares to employees pursuant to the Company’s employee share purchase plans, pursuant to the conversion
and/or exercise of Ordinary Share Equivalents outstanding as of the date of the most recently furnished report on Form 6-K under the
Exchange Act, the issuance of Ordinary Shares in offerings registered on the Company’s shelf registration statement on Form S-3
(Registration No. 333-249547), and the issuance of Ordinary Shares pursuant to an “at the market” offering of the Company’s
securities under Rule 415(a)(4) as to which a prospectus supplement to the has been filed under Rule 424(b). No Person has any right
of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the
Transaction Documents. Except pursuant to Ordinary Share Equivalents outstanding as of the date of this Agreement, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights
or obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any Ordinary
Shares or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to issue additional Ordinary Shares or Ordinary Share Equivalents or capital stock of any Subsidiary.
The issuance and sale of the Units will not obligate the Company or any Subsidiary to issue Ordinary Shares or other securities to any
Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision
that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities by the Company
or any Subsidiary. Except as set forth in the SEC Reports, there are no outstanding securities or instruments of the Company or any Subsidiary
that contain any redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the
Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. Except as set forth in the SEC
Reports, the Company does not have any share appreciation rights or “phantom share” plans or agreements or any similar plan
or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable,
have been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any shareholder,
the Board of Directors or others is required for the issuance and sale of the Units. There are no shareholders agreements, voting agreements
or other similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the knowledge of
the Company, between or among any of the Company’s shareholders.

 

    	 

     

    

 

(h)
SEC Reports; Financial Statements. The Company has filed or furnished all reports, schedules, forms, statements and other documents
required or permitted, including reports on Form 6-K, to be filed or furnished by the Company under the Securities Act and the Exchange
Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the
Company was required by law or regulation to file such material) (the foregoing materials, as may be amended, including the exhibits
thereto and documents incorporated by reference therein, together with the Prospectus, being collectively referred to herein as the “SEC
Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior
to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements
of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. The Company has never been an issuer subject to Rule 144(i)
under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable
accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such
financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International
Accounting Standards Board (“IFRS”), except as may be otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not contain all footnotes required by IFRS, and fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

 

(i)
Material Changes; Undisclosed Events, Liabilities or Developments. Since the date of the latest audited financial statements included
within the SEC Reports, except as disclosed in the SEC Reports, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice,
(B) liabilities incurred in connection with the Business Combination, and (C) liabilities not required to be reflected in the Company’s
financial statements pursuant to IFRS or disclosed in filings made with the Commission, (iii) the Company has not altered its method
of accounting, (iv) the Company has not declared or made any dividend or distribution of cash or other property to its shareholders or
purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v) the Company has not issued any
equity securities to any officer, director or Affiliate, except pursuant to existing Company share option plans. The Company does not
have pending before the Commission any request for confidential treatment of information. Except for the issuance of the Units contemplated
by this Agreement, the Business Combination or as set forth in the SEC Reports, no event, liability, fact, circumstance, occurrence or
development has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their
respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the
Company under applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed
at least one (1) Trading Day prior to the date that this representation is made.

 

(j)
Litigation. Except as disclosed in the SEC Reports, there is no material action, suit, inquiry, notice of violation, proceeding
or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their
respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state,
county, local or foreign) (collectively, an “Action”). None of the Actions set forth in the SEC Reports, (i) adversely
affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Units or (ii) could, if there
were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary,
nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal
or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not
pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the
Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed
by the Company or any Subsidiary under the Exchange Act or the Securities Act.

 

    	 

     

    

 

(k)
Labor Relations. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees
of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’
employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither
the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary,
is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third
party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability
with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all applicable local and foreign
laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except
where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect.

 

(l)
Compliance. Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor
has the Company or any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture,
loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound
(whether or not such default or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator
or other governmental authority or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental
authority, including without limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be
expected to result in a Material Adverse Effect.

 

(m)
Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating
to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating
to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well
as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders,
permits, plans or regulations, issued, entered, promulgated or approved thereunder (“Environmental Laws”); (ii) have
received all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses;
and (iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and
(iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(n)
Regulatory Permits. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate
federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports,
except where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (“Material
Permits”), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or
modification of any Material Permit.

 

(o)
Title to Assets. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them
and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries,
in each case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially
interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment
of federal, state or other taxes, for which appropriate reserves have been made therefor in accordance with IFRS and, the payment of
which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries
are held by them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance in all
material respects.

 

    	 

     

    

 

(p)
Intellectual Property. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks,
trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights
and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which
the failure to so have could have a Material Adverse Effect (collectively, the “Intellectual Property Rights”). None
of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights
has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date
of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included
within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe
upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge
of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any
of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy,
confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

(q)
Insurance. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses
and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including,
but not limited to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has knowledge of any facts or circumstances
which would cause the Company or such Subsidiary to believe that it will not be able to renew its existing insurance coverage as and
when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business without a
significant increase in cost.

 

(r)
Transactions With Affiliates and Employees. Except as set forth in the SEC Reports, none of the officers or directors of the Company
or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to
any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, shareholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including share option agreements under any share option plan of the Company.

 

(s)
Sarbanes-Oxley; Internal Accounting Controls. The Company and the Subsidiaries are in compliance in all material respects with
any and all applicable requirements of the Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable
rules and regulations promulgated by the Commission thereunder that are effective as of the date hereof and as of the Closing Date. Except
as set forth in the SEC Reports, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide
reasonable assurance that: (i) transactions are executed in accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with IFRS and to maintain asset accountability,
(iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Except as set forth in the SEC Reports, the Company and the Subsidiaries have established disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such disclosure controls
and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the
Subsidiaries as of the end of the period covered by the most recently filed annual report under the Exchange Act (such date, the “Evaluation
Date”). The Company presented in its Annual Report on Form 20-F for the year ended January 31, 2020, the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation
Date. Except as disclosed in the SEC Reports, there have been no changes in the internal control over financial reporting (as such term
is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or are reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.

 

    	 

     

    

 

(t)
Certain Fees. Except as set forth in the SEC Reports, no brokerage or finder’s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or
other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section
that may be due in connection with the transactions contemplated by the Transaction Documents.

 

(u)
Investment Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Units, will
not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
The Company shall conduct its business in a manner so that it will not become an “investment company” subject to registration
under the Investment Company Act of 1940, as amended.

 

(v)
Registration Rights. Except as set forth in the SEC Reports or as contemplated by the Transaction Documents, no Person has any
right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or
any Subsidiary.

 

(w)
Listing and Maintenance Requirements. The Ordinary Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act,
and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration
of the Ordinary Shares under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating
such registration. Except as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received
notice from any Trading Market on which the Ordinary Shares are or have been listed or quoted to the effect that the Company is not in
compliance with the listing or maintenance requirements of such Trading Market. Except as set forth in the SEC Reports, the Company is,
and has no reason to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance
requirements. The Ordinary Shares are currently eligible for electronic transfer through the Depository Trust Company or another established
clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic transfer.

 

(x)
Application of Takeover Protections. The Company and the Board of Directors have taken all necessary action, if any, in order
to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or other similar anti-takeover provision under the Company’s constitution (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their
obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company’s
issuance of the Units and the Purchasers’ ownership of the Units.

 

(y)
Disclosure. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or
counsel with any information that it believes constitutes or might constitute material, non-public information which is not otherwise
disclosed in the Prospectus. The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting
transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding
the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby is true and correct and does not
contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein,
in the light of the circumstances under which they were made, not misleading. The press releases, together with the Reports of Foreign
Private Issuer on Form 6-K, disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole
do not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in light of the circumstances under which they were made and when made, not misleading. The Company
acknowledges and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 hereof.

 

    	 

     

    

 

(z)
No Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2,
neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Units
to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market
on which any of the securities of the Company are listed or designated.

 

(aa)
Solvency. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt
by the Company of the proceeds from the sale of the Units hereunder, (i) the fair saleable value of the Company’s assets exceeds
the amount that will be required to be paid on or in respect of the Company’s existing debts and other liabilities (including known
contingent liabilities) as they mature, (ii) the Company’s assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)
the current cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after
taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature
(taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any
facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization
laws of any jurisdiction within one year from the Closing Date. For the purposes of this Agreement, “Indebtedness”
means (x) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the
ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the Company’s consolidated balance sheet (or the notes thereto), except guaranties
by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business; and (z)
the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with IFRS. Neither
the Company nor any Subsidiary is in default with respect to any Indebtedness.

 

(bb)
Tax Status. Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a
Material Adverse Effect, the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income
and all foreign income and franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)
has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii) has set aside on its books provision reasonably adequate for the payment of all material
taxes for periods subsequent to the periods to which such returns, reports or declarations apply. Except for taxes that would not, individually
or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, there are no unpaid taxes claimed to be due
by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.

 

(cc)
Foreign Corrupt Practices. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any
agent or other person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful
payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf
of which the Company is aware) which is in violation of law, or (iv) violated in any material respect any provision of FCPA.

 

    	 

     

    

 

(dd)
Accountants. The Company’s accounting firm is set in the SEC Reports. To the knowledge and belief of the Company, such accounting
firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) has expressed its opinion with respect to the
financial statements included in the Company’s Annual Report for the fiscal year ending January 31, 2021.

 

(ee)
Acknowledgment Regarding Purchasers’ Purchase of Units. The Company acknowledges and agrees that each of the Purchasers
is acting solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar
capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or
any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby
is merely incidental to the Purchasers’ purchase of the Units. The Company further represents to each Purchaser that the Company’s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the
transactions contemplated hereby by the Company and its representatives.

 

(ff)
Acknowledgment Regarding Purchaser’s Trading Activity. Anything in this Agreement or elsewhere herein to the contrary notwithstanding
(except for Sections 3.2(f) and 4.12 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been
asked by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the
Company, or “derivative” securities based on securities issued by the Company or to hold the Units for any specified term;
(ii) past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or “derivative”
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company’s publicly-traded securities; (iii) any Purchaser, and counter-parties in “derivative” transactions to
which any such Purchaser is a party, directly or indirectly, presently may have a “short” position in the Ordinary Shares,
and (iv) each Purchaser shall not be deemed to have any affiliation with or control over any arm’s length counter-party in any
“derivative” transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in
hedging activities at various times during the period that the Units (or the Ordinary Shares underlying the Units) are outstanding, and
(z) such hedging activities (if any) could reduce the value of the existing shareholders’ equity interests in the Company at and
after the time that the hedging activities are being conducted. The Company acknowledges that such aforementioned hedging activities
do not constitute a breach of any of the Transaction Documents.

 

(gg)
Regulation M Compliance. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly,
any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Units or any of the securities underlying the Units, (ii) sold, bid for, purchased, or, paid any compensation
for soliciting purchases of, any of the Units, or (iii) paid or agreed to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company, other than, in the case of clauses (ii) and (iii), offers and sales pursuant to an “at
the market” offering of the Company’s securities under Rule 415(a)(4) as to which a prospectus supplement has been filed
under Rule 424(b).

 

(hh)
[Reserved].

 

(ii)
Share Option Plans. Except as disclosed in the SEC Reports, each share option granted by the Company under the Company’s
share option plan was granted (i) in accordance with the terms of the Company’s share option plan and (ii) with an exercise price
at least equal to the fair market value of the Ordinary Shares on the date such share option would be considered granted under IFRS and
applicable law. No share option granted under the Company’s share option plan has been backdated. The Company has not knowingly
granted, and there is no and has been no Company policy or practice to knowingly grant, share options prior to, or otherwise knowingly
coordinate the grant of share options with, the release or other public announcement of material information regarding the Company or
its Subsidiaries or their financial results or prospects.

 

    	 

     

    

 

(jj)
Office of Foreign Assets Control. Neither the Company nor any Subsidiary nor, to the Company’s knowledge, any director,
officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”).

 

(kk)
U.S. Real Property Holding Corporation. The Company is not and has never been a U.S. real property holding corporation within
the meaning of Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser’s
request.

 

(ll)
Bank Holding Company Act. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company
Act of 1956, as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the
“Federal Reserve”). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly,
five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity
of a bank or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries
or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and
to regulation by the Federal Reserve.

 

(mm)
Money Laundering. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the “Money Laundering Laws”),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company
or any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.

 

3.2
Representations and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents and
warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case
they shall be accurate as of such date):

 

(a)
Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and
in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership limited
liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents
and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance
by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate,
partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to
which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof,
will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general
application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited
by applicable law.

 

(b)
Understandings or Arrangements. Such Purchaser is acquiring the Units and the securities underlying the Units as principal for
its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such securities (this representation and warranty not limiting such Purchaser’s right to sell the Units or the securities underlying
the Units pursuant to the Registration Statement or otherwise in compliance with applicable federal and state securities laws). Such
Purchaser is acquiring the Units hereunder in the ordinary course of its business.

 

(c)
Purchaser Status. At the time such Purchaser was offered the Units, it was, and as of the date hereof it is either: (i) an “accredited
investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (ii) a “qualified institutional
buyer” as defined in Rule 144A(a) under the Securities Act.

 

    	 

     

    

 

(d)
Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication
and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Units, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment
in the Units and, at the present time, is able to afford a complete loss of such investment.

 

(e)
Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed
necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the
Units and the merits and risks of investing in the Units; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment.

 

(f)
Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has
not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any
purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser
first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
pricing terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing,
in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of
such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion
of assets managed by the portfolio manager that made the investment decision to purchase the Units covered by this Agreement. Other than
to other Persons party to this Agreement or to such Purchaser’s representatives, including, without limitation, its officers, directors,
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures
made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing,
for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.

 

The
Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser’s
right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties
contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement
or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained
herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order
to effect Short Sales or similar transactions in the future.

 

ARTICLE
IV.

OTHER AGREEMENTS OF THE PARTIES

 

4.1
Furnishing of Information. Until the earlier of (x) time that no Purchaser owns Ordinary Shares underlying the Units issued hereunder
and (y) the second anniversary of the Closing, the Company covenants to timely file (or obtain extensions in respect thereof and file
within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the Exchange Act
even if the Company is not then subject to the reporting requirements of the Exchange Act.

 

4.2
Integration. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section 2 of the Securities Act) that would be integrated with the offer or sale of the Units for purposes of the rules
and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction
unless shareholder approval is obtained before the closing of such subsequent transaction.

 

    	 

     

    

 

4.3
Securities Laws Disclosure; Publicity. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material
terms of the transactions contemplated hereby, and (b) file a Report on Form 6-K, including copies of the Transaction Documents (or the
forms thereof) as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of
such press release, the Company represents to the Purchasers that it shall have publicly disclosed all material, non-public information
delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees
or agents in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of
such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement,
whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees
or Affiliates on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate. The Company and
each Purchaser shall consult with each other in issuing any other press releases with respect to the transactions contemplated hereby,
and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the
prior consent of the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with
respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure is
required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement
or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser, or include the name
of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such
Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction Documents with the Commission
and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b).

 

4.4
Shareholder Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person,
that any Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by
the Company, or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving
Units under the Transaction Documents or under any other agreement between the Company and the Purchasers.

 

4.5
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, which shall be disclosed pursuant to Section 4.3, and except with respect to the Business Combination, the Company covenants
and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or counsel with any information
that constitutes, or the Company reasonably believes constitutes, material non-public information, unless prior thereto such Purchaser
shall have consented to the receipt of such information and agreed with the Company to keep such information confidential. The Company
understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the
Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or
Affiliates delivers any material, non-public information to a Purchaser without such Purchaser’s consent, the Company hereby covenants
and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective
officers, directors, agents, employees or Affiliates, or a duty to the Company, any of its Subsidiaries or any of their respective officers,
directors, agents, employees or Affiliates not to trade on the basis of, such material, non-public information, provided that the Purchaser
shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Report on Form 6-K. The Company understands and confirms that each Purchaser shall be relying on the foregoing
covenant in effecting transactions in securities of the Company.

 

4.6
Use of Proceeds. The Company shall use the net proceeds from the sale of the Units hereunder for working capital and general corporate
purposes, including for the Business Combination, for the other transactions contemplated by the agreements governing the Business Combination
and for fees, costs and expenses incurred in connection with the Business Combination.

 

    	 

     

    

 

4.7
Indemnification of Purchasers. Subject to the provisions of this Section 4.7, the Company will indemnify and hold each Purchaser
and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding
a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”) harmless from any
and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in
settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser Party may suffer or
incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company
in this Agreement or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or
any of them or their respective Affiliates, by any shareholder of the Company who is not an Affiliate of such Purchaser Party, with respect
to any of the transactions contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such
Purchaser Party’s representations, warranties or covenants under the Transaction Documents or any agreements or understandings
such Purchaser Party may have with any such shareholder or any violations by such Purchaser Party of state or federal securities laws
or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct),
the Company will indemnify each Purchaser Party, to the fullest extent permitted by applicable law, from and against any and all losses,
claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses, as incurred, arising
out of or relating to (i) any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the
case of any prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the
extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party
furnished in writing to the Company by such Purchaser Party expressly for use therein, or (ii) any violation or alleged violation by
the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith.
If any action shall be brought against any Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such
Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with
counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position
of such Purchaser Party, in which case the Company shall be responsible for the reasonable fees and expenses of no more than one such
separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party
effected without the Company’s prior written consent, which shall not be unreasonably withheld or delayed; or (z) to the extent,
but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party’s breach of any of the representations,
warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification
required by this Section 4.7 shall be made by periodic payments of the amount thereof during the course of the investigation or defense,
as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action
or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject to pursuant to law.

 

4.8
Listing of Ordinary Shares. Until the earlier of (x) time that no Purchaser owns any Ordinary Shares underlying the Units sold
hereunder and (y) the second anniversary of the Closing, the Company hereby agrees to use best efforts to maintain the listing or quotation
of the Ordinary Shares on the Trading Market on which it is currently listed, and concurrently with the date hereof, the Company shall
submit a listing of additional shares notice to Nasdaq with respect to the issuance of the Ordinary Shares underlying the Units to be
sold hereunder (including the Warrant Shares) and use its best efforts to obtain a no objections notice from Nasdaq or otherwise to promptly
secure the listing of all of the Ordinary Shares on Nasdaq. The Company further agrees, if the Company applies to have the Ordinary Shares
traded on any other Trading Market, it will then include in such application all of the Ordinary Shares, and will take such other action
as is necessary to cause all of the Ordinary Shares to be listed or quoted on such other Trading Market as promptly as possible. The
Company will then take all action reasonably necessary to continue the listing and trading of its Ordinary Shares on a Trading Market
and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
the Trading Market. The Company agrees to maintain the eligibility of the Ordinary Shares for electronic transfer through the Depository
Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the Depository
Trust Company or such other established clearing corporation in connection with such electronic transfer.

 

    	 

     

    

 

4.9
Ownership Requirement. On the date of the Extraordinary General Meeting, Investor shall own such number of Ordinary Shares at
least equal to the number of Ordinary Shares it received from the Company on the Closing Date.

 

4.10
[Reserved].

 

4.11
Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to such Transaction Document. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Units, or the Ordinary Shares underlying the Units, or otherwise.

 

4.12
Certain Transactions and Confidentiality. Each Purchaser, severally and not jointly with the other Purchasers, covenants that
neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including
Short Sales of any of the Company’s securities during the period commencing with the execution of this Agreement and ending at
such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as
described in Section 4.3. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the
transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described
in Section 4.3, such Purchaser will maintain the confidentiality of the existence and terms of this transaction. Notwithstanding the
foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that
(i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities
of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section 4.3, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any
securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by
this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.3 and (iii) no Purchaser
shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company or its Subsidiaries after
the issuance of the initial press release as described in Section 4.3. Notwithstanding the foregoing, in the case of a Purchaser that
is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and
the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of
such Purchaser’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Units covered by this Agreement.

 

4.13
Registration Statement. As promptly as practicable following the Closing Date, but in any event not later than five (5) Business
Days following the Closing, the Company shall file the Prospectus with the Commission pursuant to Rule 424(b). At the time the Registration
Statement became effective, the Registration Statement conformed in all material respects to the requirements of the Securities Act and
did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary
to make the statements therein not misleading. At the time the Prospectus will be issued, the Prospectus will conform in all material
respects to the requirements of the Securities Act and will not contain an untrue statement of a material fact or omit to state a material
fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
If at any time the number of shares available for resale under the Prospectus is less than the sum of (i) the number of the Ordinary
Shares included in the Units then held by the Purchasers, plus (ii) the number of Warrants Shares then held by the Purchasers, plus (iii)
the number of Warrants Shares issuable upon cash exercise of the Warrants then held by the Purchasers, then the Company shall as promptly
as reasonably practicable file an additional Prospectus to the Registration Statement or shall file a new registration statement, in
either case covering the resale of a number of Ordinary Shares equal to the number Ordinary Shares and Warrant Shares then held by the
Purchasers, plus 150% of the number of Warrant Shares then issuable upon cash exercise of the Warrants then held by the Purchasers.
Notwithstanding anything herein to the contrary, the Company may take into account the position of the staff of the Commission with respect
to the date on which the Staff will permit any additional Prospectus or new registration statement to be filed with the SEC, and the
number of Ordinary Shares to be included in any additional Prospectus or new registration statement, and shall not be deemed to be in
breach of this Section 4.13 by virtue thereof.

 

    	 

     

    

 

4.13
Warrant Shares. The Company shall use its best efforts to keep effective the Registration Statement registering the resale of
the Warrant Shares. If at any time the Registration Statement (or any subsequent registration statement registering the sale or resale
of the Warrant Shares) is not effective or is not otherwise available for the Warrant Shares, the Company shall promptly notify the holders
of the Warrants that such registration statement is not then effective and thereafter shall promptly notify the holders of the Warrants
when the Registration Statement or a new registration statement becomes effective for the sale or resale of the Warrant Shares (it being
understood that the foregoing shall not limit the ability of the Company to issue, or any purchaser to sell, such Ordinary Shares in
compliance with an exemption from registration under the Securities Act).

 

ARTICLE
V.

MISCELLANEOUS

 

5.1
Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if (i)
the Company has not received a “no objections” letter from Nasdaq with respect to the issuance of the Units within fifteen
(15) days from the date hereof, (ii) the closing price of the Ordinary Shares as reported by Bloomberg on any Trading Day is more than
40% less than the closing price of the Ordinary Shares on the date hereof, as reported by Bloomberg, or (iii) the Closing has not been
consummated on or before the fifteenth (15th) Trading Day following the date hereof; provided, however, that
no such termination will affect the right of any party to sue for any breach by any other party (or parties). All determinations of the
closing price of the Ordinary Shares shall be subject to adjustment for reverse and forward share splits, share dividends, share combinations
and other similar transactions of the Ordinary Shares.

 

5.2
Fees and Expenses. At the Closing, the Company has agreed to pay MWE the sum of $25,000 as reimbursement of the Purchasers for
their legal fees and expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees
and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident
to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees
(including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company), stamp
taxes and other taxes and duties levied in connection with the delivery of any Units to the Purchasers.

 

5.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, and the Prospectus contain the
entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

5.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in
writing and shall be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is
delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or email attachment at the email address as set forth on the
signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)
the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service
or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages attached hereto. To the extent that any notice provided pursuant to any Transaction Document
constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
file such notice with the Commission pursuant to a Report on Form 6-K.

 

    	 

     

    

 

5.5
Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Units based on the
initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and the Company.

 

5.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to
limit or affect any of the provisions hereof.

 

5.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and
permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent
of each Purchaser (other than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom
such Purchaser assigns or transfers any Units or securities underlying the Units, provided that such transferee agrees in writing to
be bound, with respect to the transferred securities, by the provisions of the Transaction Documents that apply to the “Purchasers.”

 

5.8
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise
set forth in Section 4.7 and this Section 5.8.

 

5.9
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the
principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and
defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto
or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or
in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of
any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any Action or Proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient
venue for such Proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law. If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction
Documents, then, in addition to the obligations of the Company under Section 4.7, the prevailing party in such Action or Proceeding shall
be reimbursed by the non-prevailing party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such Action or Proceeding.

 

5.10
Survival. The representations and warranties contained herein shall survive the Closing and the delivery of the Units.

 

    	 

     

    

 

5.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one
and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party,
it being understood that the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or by e-mail delivery of a “.pdf” format data file, or any electronic signature complying with the U.S. federal ESIGN Act
of 2000, the Uniform Electronic Transactions Act, or other applicable law (e.g., www.docusign.com), such signature shall create a valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such
facsimile, “.pdf” or electronic signature page were an original thereof.

 

5.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to
be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

 

5.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights; provided, however, that in the case of a rescission of an exercise
of a Warrant, the Purchaser shall be required to return the Warrant Shares received upon such exercise concurrently with the return to
such Purchaser of the aggregate exercise price paid and the restoration of the Purchaser’s right to acquire such Warrant Shares
pursuant to such Warrant.

 

5.14
Replacement of Securities. If any certificate or instrument evidencing any Units, or the Ordinary Shares, Warrants, or Warrant
Shares issuable thereunder, is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution
for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate or instrument,
but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new
certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated
with the issuance of such replacement securities.

 

5.15
Remedies. In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages,
each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction
Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that
a remedy at law would be adequate.

 

5.16
Payment Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise
or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by
or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including,
without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such
restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect
as if such payment had not been made or such enforcement or setoff had not occurred.

 

    	 

     

    

 

5.17
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as
a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way
acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each
Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of
this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation
of the Transaction Documents. For reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to
communicate with the Company through MWE. The Company has elected to provide all Purchasers with the same terms and Transaction Documents
for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood
and agreed that each provision contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser,
solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers.

 

5.18
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.

 

5.19
Construction. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against
the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and Ordinary Shares in any Transaction Document shall be subject to adjustment for reverse and forward
share splits, share dividends, share combinations and other similar transactions of the Ordinary Shares that occur after the date of
this Agreement.

 

5.20
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY
ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO
THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY
JURY.

 

(Signature
Pages Follow)

 

    	 

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above.

 

	Naked
    brand group limited	 	Address
    for Notice:
	 	 	 	 
	By:	     	 	E-Mail:
	Name:	 	 	Fax:
	Title:	 	 	 

 

With
a copy to (which shall not constitute notice):

 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE
PAGE FOR PURCHASER FOLLOWS]

 

    	 

     

    

 

[PURCHASER
SIGNATURE PAGES TO NAKD SECURITIES PURCHASE AGREEMENT]

 

IN
WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

Name
of Purchaser: ________________

 

Signature
of Authorized Signatory of Purchaser: _________________________________

 

Name
of Authorized Signatory:

Title
of Authorized Signatory:

Email
Address of Authorized Signatory:

 

Address
for Notice to Purchaser:

 

with
a copy (for informational purposes only) to:

 

McDermott
Will & Emery LLP

340
Madison Ave.

New
York, NY 10173

Telephone:
(212) 547-5885

E-mail:
Rcohen@mwe.com

dwoodard@mwe.com

Attention:
Robert Cohen, Esq.

 

Address
for Delivery of Units to Purchaser (if not same as address for notice):

 

Subscription
Amount:

 

Units:
_________________

 

EIN
Number:

 

[  ] Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i) the obligations of the above-signed
to purchase the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the
Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be disregarded, (ii)
the Closing shall occur on the first (1st) Trading Day following the date of this Agreement and (iii) any condition to Closing
contemplated by this Agreement (but prior to being disregarded by clause (i) above) that required delivery by the Company or the above-signed
of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead
be an unconditional obligation of the Company or the above-signed (as applicable) to deliver such agreement, instrument, certificate
or the like or purchase price (as applicable) to such other party on the Closing Date.

 

    	 

     

    

 

EXHIBIT
A

Form
of Warrant

 

[Attached]gmvp_ex101.htm

EXHIBIT 10.1
  
 AMENDED AND RESTATED ASSET PURCHASE AGREEMENT
  
 THIS AMENDED AND RESTATED ASSET PURCHASE AGREEMENT (the “Agreement”) is entered into as of November 5, 2021, by and between GRIDIRON BIONUTRIENTS, INC., a Nevada corporation (“Purchaser”), ST BIOSCIENCES, LTD., a company organized under the laws of England and Wales (“Seller”) and Jason Frankovich, an individual residing in the State of New York (“Frankovich”). Certain capitalized terms used but not otherwise defined in this Agreement are defined as set forth in Exhibit A. 
  
 WHEREAS, Seller is engaged in the Business and owns the Transferred Assets;
  
 WHEREAS, Frankovich owns a majority of issued and outstanding ordinary shares of £0.001 each of Seller and will materially benefit from the transactions contemplated by this Agreement;
  
 WHEREAS, Seller and Purchaser entered into that certain Asset Purchase Agreement dated as of October 27, 2021 (the “Original APA”) pursuant to which Purchaser agreed to purchase from Seller, and Seller agreed to sell to Purchaser, the Transferred Assets on the terms, and subject to the conditions, set forth therein; and
  
 WHEREAS, Seller and Purchaser now wish to amend and restate the Original APA in its entirety as set forth in this Agreement. 
  
 NOW, THEREFORE, in consideration of the promises, agreement and covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement, intending to be legally bound, agree as follows:
  
 1. SALE OF TRANSFERRED ASSETS; RELATED TRANSACTIONS.
  
 1.1 Sale of Transferred Assets. At the Closing, Seller shall cause to be sold, assigned, transferred, conveyed and delivered to Purchaser all of the Transferred Assets, with full title guarantee, free of any Encumbrances (except for the Permitted Encumbrance), on the terms and subject to the conditions set forth in this Agreement. 
  
 1.2 Purchase Price. As consideration for the sale, assignment, transfer, conveyance and delivery of the Transferred Assets to Purchaser, on the date hereof, Purchaser shall issue to Seller 19,831,623 shares of common stock, par value $0.001 per share, of Purchaser (the “Shares”). The Shares will be issued to Seller pursuant to an exemption from the registration requirements under the Securities Act of 1933, as amended (the “Securities Act”), and will accordingly bear applicable restricted securities legends. 
  
 1.3 Assumption of Liabilities. Purchaser shall, and hereby does, assume and agree to pay, perform and discharge the Liabilities of Seller arising under the Assigned Contracts following the Closing, in each case in accordance with the stated written terms thereof (the “Assumed Liabilities”). Except for the Assumed Liabilities, Purchaser shall not assume any Liabilities of Seller (whether or not related to the Transferred Assets), and it is understood that Purchaser is expressly disclaiming any express or implied assumption of any Liabilities of Seller other than the Assumed Liabilities. 
  
 1.4 Closing. The closing of the sale of the Transferred Assets to Purchaser and the other Transactions (the “Closing”) shall take place immediately following the execution and delivery of this Agreement on the date hereof (the “Closing Date”). The following actions have been taken or will be taken simultaneously with the Closing: 
  
 	 
	1
	

	 

  
 (a) The board of directors of each of Purchaser and Seller shall have approved the execution, delivery and performance of this Agreement and the Transactions.
  
 (b) The board of directors of Purchaser shall have taken all necessary corporate action (including the filing of the Schedule 14f-1 as contemplated by Section 6.3 and the expiration of the 10 day period required by Rule 14f-1 under the Exchange Act) to cause the following to occur as of the Closing: (i) the board of directors of Purchaser shall consist of Timothy Orr (“Orr”) and Jeff Kraws (“Kraws”) immediately following the Closing, (ii) immediately following the expiration of the 10 day period required by Rule 14f-1 under the Exchange Act, Frankovich will be appointed to the board of directors of Purchaser without any further action required by the board of directors of Purchaser, and (iii) the Chief Executive Officer of Purchaser shall be Jeff Kraws and the Interim Chief Financial Officer of Purchaser shall be Timothy Orr. The board of directors of Purchaser will have a minimum of three members (following the appointment of Frankvoich) and maximum of five members until the earlier of 18 months after the Closing Date or the date Purchaser’s common stock is listed on a U.S. national securities exchange. 
  
 (c) Each of the third-party Consents set forth on Schedule 1.4(c) shall have been obtained.
  
 (d) Each of Seller and Purchaser shall have executed and delivered: (i) a bill of sale evidencing the transfer and assignment of the Transferred Assets from Seller to Purchaser; (ii) an assignment and assumption agreement evidencing the assignment by Seller, and the assumption by Purchaser of the Assumed Contracts; and (iii) assignment agreements in recordable form evidencing the transfer and assignment of the Intellectual Property and Intellectual Property Rights covered by this Agreement, in each case in form and substance reasonably satisfactory to both parties.
  
 (e) The Salzman IP shall have been transferred and assigned to Purchaser pursuant to assignment documentation containing, among other things, representations, warranties and indemnities regarding ownership thereof, in form and substance reasonably satisfactory to Purchaser.
  
 (f) Purchaser shall have instructed its transfer agent in writing to issue the Shares to Seller via book-entry in the Purchaser’s stock ledger.
  
 (g) Each of Frankovich, Kraws, John Driscoll, Dr. Andrew Salzman and Jamie Lynn Coulter shall have executed and delivered to Seller and Purchaser (and each of Seller and Purchaser shall have executed and delivered) a tripartite settlement agreement acknowledging the termination of each of their respective employment agreements with Seller and waiving all rights to receive unpaid wages, salary and other benefits thereunder. 
  
 (h) Frankovich shall have executed and delivered the Lock-up / Leak-out Agreement attached hereto as Exhibit B.
  
 2. REPRESENTATIONS AND WARRANTIES OF SELLER.
  
 Seller and Frankovich hereby, jointly and severally, represent and warrant to Purchaser as follows:
  
 2.1 Due Organization. Seller is duly organized, validly existing and in good standing under the laws of England and Wales. Seller has the requisite corporate power and authority to own or otherwise hold the assets held by it and to carry on the Business as now being conducted. Seller has delivered to Purchaser accurate and complete copies of: (i) the governing documents of Seller, including all amendments thereto.
  
 	 
	2
	

	 

  
 2.2 Title to Transferred Assets. The Seller owns, and has good, valid and marketable title to, all of the Transferred Assets, free and clear of any Encumbrances, except for the Permitted Encumbrance and, at Closing, will convey to Purchaser good, valid and marketable title to all of the Transferred Assets, free and clear of all Encumbrances, except for the Permitted Encumbrance.
  
 2.3 Authority; Binding Nature of Agreements. Seller has full corporate power and authority to execute this Agreement and the other Transactional Agreements to which it is, or is specified to be, a party and to consummate the Transactions. Frankovich has the legal capacity to execute this Agreement and the other Transactional Agreements to which he is, or is specified to be, a party and to consummate the Transactions. Seller has taken all corporate action required to authorize the execution and delivery of this Agreement and the other Transactional Agreements to which it is, or is specified to be, a party and to authorize the consummation of the Transactions. Each of Seller and Frankovich has duly executed and delivered this Agreement and each other Transactional Agreement to which it/he is, or is specified to be, a party, and this Agreement and each other Transactional Agreement to which it/he is, or is specified to be, a party constitutes its legal, valid and binding obligation, enforceable against Seller and Frankovich in accordance with its respective terms.
  
 2.4 Non-Contravention; Consents. The execution and delivery by Seller and Frankovich of this Agreement and of each other Transactional Agreement to which it/he is, or is specified to be, a party do not, and the consummation of the Transactions by it/him pursuant to this Agreement and the other Transactional Agreements, will not conflict with, or result in any breach of or constitute a default under or result in the creation of any Encumbrance upon any of the Transferred Assets or the Business, or under (a) the organizational documents of Seller, (b) except as set forth in Schedule 1.4(c), any Contract to which Seller is a party or by which any of the Transferred Assets are bound or which relates to the Transferred Assets or the Business, or (c) any judgment, order or decree (“Judgment”) or statute, law, ordinance, rule or regulation applicable to Seller or Frankovich (“Applicable Law”) or all or any portion of the Transferred Assets or the Business. No Consent or registration, declaration or filing with, any Governmental Body is required to be obtained or made by or with respect to Seller or Frankovich in connection with the execution, delivery and performance of this Agreement, the other Transactional Agreement or the consummation of the Transactions.
  
 2.5 Tangible Property. Schedule 2.5 contains a correct, current and complete list of all of the Tangible Property (the “Business Tangible Property”) used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Transferred Assets as currently conducted. The Business Tangible Property is in good operating condition, normal wear and tear excepted. No Consent of any Person is needed to that the interest of Seller shall continue to be in full force and effect and enforceable by Purchaser following the Closing.
  
 2.6 Intellectual Property. Schedule 2.6 contains a correct, current, and complete list of all of the Intellectual Property and Intellectual Property Rights (the “Business Intellectual Property”) used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Transferred Assets as currently conducted. Seller is the sole and exclusive legal and beneficial owner of all right, title and interest in and to the Business Intellectual Property and has the valid and enforceable right to use all other Business Intellectual Property used or held for use in or necessary for the conduct of the Business as currently conducted, in each case, free and clear of Encumbrances, other than the Permitted Encumbrances. Other than as set forth on Schedule 2.6, no person other than Seller is or was involved in or has contributed to the invention, creation, or development of any Business Intellectual Property.
  
 	 
	3
	

	 

  
 2.7 Contracts. Schedule 2.7 contains a correct, current, and complete list of all Contracts (the “Business Contracts”) to which Seller or any of its Affiliates is a party, and rights of Seller or any of its Affiliates, as applicable, under all Contracts, that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Transferred Assets. Each Business Contract is valid and binding on Seller in accordance with its terms and is in full force and effect. None of Seller or, to the knowledge of Seller or Frankovich, any other party thereto is in breach of or default under (or is alleged to be in breach of or default under), or has provided or received any notice of any intention to terminate, any Business Contract. No event or circumstance has occurred that, with notice or lapse of time or both, would constitute an event of default under any Business Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder. Complete and correct copies of each Business Contract (including all modifications, amendments, and supplements thereto and waivers thereunder) have been made available to Purchaser.
  
 2.8 Permits. Schedule 2.8 contains a correct, current, and complete list of all Permits (the “Business Permits”) that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Transferred Assets. All of the Business Permits have been legally obtained and maintained and are in full force and effect. None of Seller, Frankovich or any of their respective Affiliates, the Business or any of the Transferred Assets is in violation of or is being operated in violation of the terms of any Business Permit. Neither the execution and delivery of this Agreement nor the performance of any of the Transactions will: (i) require any assignment, consent, waiver or other action in respect of any Business Permit; (ii) result in the termination or modification of any Business Permit; or (iii) result in a need for additional Permits.
  
 2.9 Entire Business; Sufficiency of Assets. The Transferred Assets constitute all of the assets, properties and rights used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business and are adequate to conduct the Business. Immediately following the Closing, neither Seller, Frankovich nor any of their respective Affiliates will own or lease any assets, properties or rights that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business. There are no material facilities, services, assets or properties (including Intellectual Property) that are used or held for use by Seller or Frankovich in the conduct or operation of the Business and that are not required to be transferred to Purchaser pursuant to the provisions of this Agreement. Upon the consummation of the Transactions, Purchaser will have acquired good and marketable title in and to, or a valid leasehold interest in, each of the Transferred Assets free and clear of all Encumbrances, other then the Permitted Encumbrance.
  
 2.10 Undisclosed Liabilities. Other than as set forth on Schedule 2.10, Seller has no liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured, or otherwise.
  
 2.11 Legal Proceedings. There are no actions, demands, suits, arbitration proceedings, citations, summons, subpoenas or investigations by or before any Governmental Body (collectively, “Actions”) pending or, to the knowledge of Seller or Frankovich, threatened (a) against or by Seller or any of its Affiliates; or (b) against or by Seller, Frankovich or any of their respective Affiliates that challenges or seeks to prevent, enjoin or delay the transactions contemplated by this Agreement. No event has occurred or circumstances exist that may give rise to, or serve as a basis for, any such Action. There are no outstanding Judgments, penalties or awards against or affecting Seller, the Transferred Assets or the Business.
  
 2.12 Compliance with Laws. Seller has complied, and is now complying, with all Applicable Law. No claims have been field against Seller alleging a violation of any Applicable Law, and Seller has not received any notice of any such violation.
  
 	 
	4
	

	 

  
 2.13 Taxes. All Tax Returns required to be filed on or before the Closing by Seller have been, or will be, timely filed. Such Tax Returns are, or will be, true, complete and correct in all respects. All Taxes due and owing by Seller (whether or not shown on any Tax Return) have been, or will be, timely paid. No claim has been made by any taxing authority in any jurisdiction where Seller does not file Tax Returns that it is, or may be, subject to Tax by that jurisdiction. No extensions or waivers of statutes of limitations have been given or requested with respect to any Taxes of Seller. Seller is not a party to any Action by any taxing authority. There are no pending or threatened Actions against Seller or any of the Transferred Assets by any taxing authority. There are no Liens for Taxes (other than for current Taxes not yet due and payable) upon the Transferred Assets or any other assets of Seller. 
  
 2.14 Brokers. Seller has not agreed or become obligated to pay, or taken any action that would reasonably be expected to result in any Person claiming to be entitled to receive, any brokerage commission, finder’s fee or similar commission or fee in connection with any of the Transactions.
  
 2.15 Full Disclosure. No representation or warranty of Seller or Frankovich contained in this Agreement or any of the other Transactional Agreements, and no statement of Seller or Frankovich contained in any schedule to this Agreement, contains any untrue statement of a material fact or omits a material fact necessary to make the statement contained herein and therein, in light of the circumstances under which they were made, not misleading. Neither Seller nor Frankovich is aware of any fact that has specific application to, and that may materially adversely affect the financial condition, results of operations or prospects of Seller, the Business, the Product or the Transferred Assets.
  
 3. REPRESENTATIONS AND WARRANTIES OF PURCHASER.
  
 Purchaser represents and warrants to Seller as follows:
  
 3.1 Due Organization. Purchaser is a corporation organized, validly existing and in good standing under the laws of the State of Nevada. Purchaser has the requisite corporate power and authority to own or otherwise hold the assets held by it and to carry on its business as now being conducted. Purchaser’s organizational documents have been filed as exhibits to the SEC Filings (as defined below).
  
 3.2 Authority. Purchaser has full corporate power and authority to execute this Agreement and the other Transactional Agreements to which it is, or is specified to be, a party and to consummate the Transactions. Purchaser has taken all corporate action required to authorize the execution and delivery of this Agreement and the other Transactional Agreements to which it is, or is specified to be, a party and to authorize the consummation of the Transactions. Purchaser has duly executed and delivered this Agreement and each other Transactional Agreement to which it is, or is specified to be, a party, and this Agreement and each other Transactional Agreement to which it is, or is specified to be, a party constitutes its legal, valid and binding obligation, enforceable against Purchaser in accordance with its respective terms. 
  
 3.3 Non-Contravention; Consents. The execution and delivery by Purchaser of this Agreement and of each other Transactional Agreement to which it is, or is specified to be, a party do not, and the consummation of the Transactions by it pursuant to this Agreement and the other Transactional Agreements, will not conflict with, or result in any breach of or constitute a default under (a) the organizational documents of Purchaser, (b) any Contract to which Purchaser is a party or by which any of its assets are bound, or (c) any Judgment or Applicable Law. No Consent or registration, declaration or filing with, any Governmental Body is required to be obtained or made by or with respect to Purchaser in connection with the execution, delivery and performance of this Agreement, the other Transactional Agreement or the consummation of the Transactions.
  
 	 
	5
	

	 

  
 3.4 Capitalization. The authorized capital stock of Purchaser consists of (a) 200,000,000 shares of common stock, of which 188,616 are outstanding, and (b) 25,000,000 shares of “blank check” preferred stock, of which (i) 2,694,514 shares are designated series B convertible preferred stock, all of which are outstanding, and (ii) 2,694,514 shares are designated series B-1 convertible preferred stock, of which 673,628 are outstanding and the remainder of which may be issued pursuant to the terms of the series B-1 purchase agreement, dated September 1, 2021, between Purchaser and Lincoln Park Capital Fund, LLC. Except as set forth in this Section 3.5, Purchaser does not have any outstanding securities.
  
 3.5 SEC Filings. Purchaser has made available to Seller through the EDGAR system, true and complete copies of Purchaser’s most recent Annual Report on Form 10-K for the fiscal year ended August 31, 2020 (“10-K”), and all other reports filed by Purchaser pursuant to Sections 13(a), 13(e), 14 and 15(d) of the Exchange Act since the filing of the 10-K (collectively, the “SEC Filings”). The SEC Filings are the only filings required of Purchaser pursuant to the Exchange Act for such period. Purchaser and its subsidiaries are engaged in all material respects only in the business described in the SEC Filings and the SEC Filings contain a complete and accurate description in all material respects of the business of Purchaser and its subsidiaries, taken as a whole. There are no outstanding or unresolved comments in comment letters received from the SEC staff with respect to any SEC Filings and, to the knowledge of Purchaser, none of the SEC Filings is the subject of any ongoing SEC review. 
  
 3.6 Registration Exemption. Subject in part to the truth and accuracy of Seller’s representations in this Agreement, the offer, sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of the Securities Act. All Shares shall, upon issuance thereof by Purchaser, be duly authorized, validly issued, fully paid and non-assessable.
  
 3.7 Brokers. Purchaser has not agreed or become obligated to pay, or taken any action that would reasonably be expected to result in any Person claiming to be entitled to receive, any brokerage commission, finder’s fee or similar commission or fee in connection with any of the Transactions.
  
 3.8 No Other Representations. Except as expressly set forth in this Agreement, neither Purchaser nor any of its agents, employees or representatives has made, nor are any of them making any representation or warranty, written or oral, express or implied, including any representations and warranties about the accuracy or completeness of any information or documents previously provided, and any such other representations or warranties are hereby expressly disclaimed. 
  
 4. EMPLOYEES
  
 4.1 Seller warrants that no contract of employment of any Employee and no liability in respect of the employment of any Employee (or the termination of such employment) will transfer under operation of law or otherwise to the Purchaser or any agent or subcontractor of Purchaser on commencement of this Agreement.
  
 4.2 Notwithstanding the provisions of clause 4.1 above, if any Employee becomes employed or alleges that they have become employed by Purchaser or any agent or subcontractor of Purchaser by operation of TUPE, Purchaser or any agent or subcontractor of Purchaser will be entitled to dismiss that individual within four weeks of receiving notification of such employment or alleged employment, and, in such circumstances (or if the Employee resigns during such period), the Seller shall indemnify Purchaser on its own behalf and on behalf of its agents and subcontractors and keep Purchaser indemnified against any and all Liabilities in relation to and arising out of the employment of such individual and of that dismissal (including without limitation any Liabilities relating to any failure to inform or consult pursuant to any statutory provision), provided that Purchaser promptly (and in any event within seven days of receiving notice of such transfer or alleged transfer) notifies Seller of the Employee’s transfer or alleged transfer.
  
 	 
	6
	

	 

  
 4.3 If any individual whose employment with Seller terminated prior to the Closing Date alleges that any Liability arising from his or her employment or the termination of such employment transfers to the Purchaser any agent or subcontractor of the Purchaser (as appropriate) by operation of TUPE, Seller shall indemnify Purchaser on its own behalf and on behalf of its agents and subcontractors and shall keep Purchaser indemnified in respect of such Liability to the fullest extent permitted by law.
  
 4.4 If Purchaser or any agent or subcontractor of Purchaser (as appropriate) chooses not to terminate the employment of any Employee pursuant to Section 4.2, Seller shall indemnify Purchaser on its own behalf and on behalf of any agent or subcontractor of Purchaser against all Liabilities relating to or arising out of any claim by such Employee or any trade union, employee association or worker representative of such Employee arising during, from or in connection with their employment with Seller or any agent or subcontractor of Seller
  
 5. SURVIVAL; INDEMNIFICATION.
  
 5.1 Survival. The representations, warranties, covenants and agreements of the parties contained herein and all related rights to indemnification shall survive the Closing for a period of two years.
  
 5.2 Indemnification by Seller and Frankovich. From and after the Closing, Seller and Frankovich shall, jointly and severally, indemnify, defend and hold harmless Purchaser and its Affiliates and each of their respective officers, directors, employees, stockholders, members, partners, agents and representatives from and against any and all claims, losses, damages, liabilities, obligations, costs, debts, penalties, fines, expenses or costs of any kind, including, without limitation, reasonable legal fees and the cost of enforcing any right of indemnification hereunder (collectively, “Losses”), to the extent arising or resulting from: (i) any breach of any representation, warranty or covenant of Seller and Frankovich contained in this Agreement or any of the other Transactional Agreements; (ii) except for the Assumed Liabilities, Liabilities of Seller, including, without limitation, Liabilities relating to product liability and product warranty claims in connection with Product sold, distributed or made available prior to the Closing; (iii) the operation of the Transferred Assets or the Business prior to the Closing; (iv) all Taxes of Seller consistent with the provisions of Section 5.4, including, without limitation, all taxes attributable to Seller’s ownership and operation of the Transferred Assets and the Business prior to the Closing; or (v) Seller’s past, present and future employees.
  
 5.3 Equity Clawback. Upon settlement or adjudication of any claim for indemnification brought by Purchaser against Seller and/or Frankovich pursuant to this Section 5 (a “Indemnity Claim Determination”), Purchaser may elect, in its sole discretion, to have all or any portion of such Losses (the “Elected Amount of Losses”) satisfied through a cancellation of such number of Shares held by Seller or Frankovich equal to the quotient obtained by dividing (i) the Elected Amount of Losses, by (ii) the Relevant Share Price. The rights of Purchaser pursuant to this Section 5.3 shall be exercised by providing written notice to Purchaser’s transfer agent, Seller and Frankovich and without any action required on the part of Seller or Frankovich. For purposes of this Section 5.3, each of Seller and Frankovich hereby irrevocably constitutes and appoints Purchaser, with full power of substitution and resubstitution, as its/his true and lawful attorney to transfer Shares subject to this Section 5.3 on the books of Purchaser.
  
 6. CERTAIN COVENANTS.
  
 6.1 Registration of Shares. Within 180 days following the Closing, Purchaser shall prepare and file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 covering the resale of the Shares that are not then registered on an effective registration statement for an offering to be made on a continuous basis pursuant to Rule 415 promulgated under the Securities Act. Purchaser shall use its commercially reasonable efforts to cause such registration statement to be declared effective under the Securities Act as promptly as practicable after the filing thereof and shall use its commercially reasonable efforts to keep such registration statement continuously effective under the Securities Act until the date that all of the Shares covered by such registration statement (i) have been sold, thereunder or pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for Purchaser to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to Purchaser pursuant to a written opinion letter to such effect, addressed and acceptable to Purchaser’s transfer agent.
  
 	 
	7
	

	 

  
 6.2 Remuneration to Former CEO. At the Closing, Purchaser shall make a payment to Orr in the aggregate amount of $151,930.00 by wire transfer of immediately available funds to an account designated in writing by Orr in respect of the following: (a) $43,930 in full satisfaction of a loan made to Purchaser by Orr; and (b) $108,000 in full satisfaction of all payment and other obligations of Purchaser to Orr pursuant to that certain employment offer letter between Purchaser and Orr dated August 1, 2021 (which agreement shall be deemed terminated and of no further force or effect following receipt of such payment by Orr). In addition, in his new capacity as director and Interim Chief Financial Officers of Purchaser following the Closing (which role shall be in effect for a period of at least six months following the Closing), Orr shall (i) have joint signature authority approved by Purchaser’s board of directors on all payments made by Purchaser in excess of $7,500, (ii) lead Purchaser’s filing of all reports pursuant to Securities Exchange Act of 1934, as amended, and the filing of the registration statement pursuant to Section 6.2, in each case subject to appropriate review and input from Purchaser’s Chief Executive Officer and, as applicable, board of directors and with an accounting firm and legal counsel determined by the board of directors and (iii) be entitled to annual salary, bonus, benefits and equity grants (including, without limitation, stock options, restricted stock and restriction stock units) commensurate with other executive officers and directors of Purchaser.
  
 6.3 Schedule 14f-1. As soon as reasonably practicable after the date hereof, Purchaser will file with the SEC and transmit to Purchaser’s stockholders an information statement containing the information required by Section 14(f) of the Exchange Act and Rule 14f-1 thereunder (the “Schedule 14f-1”). Purchaser and Seller will reasonably cooperate on the preparation of the Schedule 14f-1, will each promptly provide the other party with the information relating to it or its directors and officers required under Section 14(f) of the Exchange Act and Rule 14f-1 and will take all such other actions as may reasonably be requested by the other party in connection with the preparation and filing of the Schedule 14f-1. Purchaser shall be responsible all costs and expenses in connection with the preparation and filing of the Schedule 14f-1. 
  
 6.4 Historical Financial Statements. If Purchaser determines that historical financial statements of Seller are required under applicable law to be filed by Purchaser with the SEC following the Closing, Seller agrees to use commercially reasonable efforts to cooperate as reasonably requested by Purchaser in connection with Purchaser’s preparation of such historical financial statements. Such cooperation shall include providing, as promptly as reasonably practicable, such financial and operating data regarding Seller relating to periods prior to Closing as is reasonably requested by Purchaser to the extent that the same is reasonably ascertainable by Seller from its books and records and to use commercially reasonable efforts to assist Purchaser in preparing such financial and operating data regarding Seller relating to periods prior to Closing as may be required to prepare such historical financial statements, and to provide reasonable and customary management representation letters and to use commercially reasonable efforts to assist Purchaser in Purchaser’s efforts to obtain auditor consents, and providing reasonable access during normal business hours to personnel of Seller, in each case as reasonably requested by Purchaser. Purchaser shall be responsible all costs and expenses in connection with the preparation and audit of historical financial statements for Seller after the Closing.
  
 	 
	8
	

	 

  
 6.5 Further Actions. From and after the date of this Agreement, without any further consideration, Seller shall cooperate with Purchaser and shall execute and deliver such documents and take such other actions as Purchaser may reasonably request (prior to, at or after the Closing) for the purpose of evidencing the Transactions and putting Purchaser in possession and control of all of the Transferred Assets. 
  
 6.6 Specific Performance. Seller acknowledges and affirms that in the event of Seller’s breach of this Agreement, money damages may be inadequate and Purchaser may have no adequate remedy at law. Accordingly, Seller agrees that Purchaser shall have the right, in addition to any other rights and remedies existing in its favor, to seek to enforce its rights and Seller’s obligations hereunder not only by an action or actions for damages but also by an action or actions for specific performance, injunctive and/or other equitable relief.
  
 6.7 Tax Matters.
  
 (a) Tax Cooperation and Exchange of Information. Seller and Purchaser shall provide each other with such cooperation and information as either of them reasonably may request of the other (and Seller shall cause its Affiliates to provide such cooperation and information) in filing any Tax Return, amended Tax Return or claim for refund, determining a liability for Taxes or a right to a refund of Taxes or participating in or conducting any audit or other proceeding in respect of Taxes. Such cooperation and information shall include providing copies of relevant Tax Returns or portions thereof, together with related work papers and documents relating to rulings or other determinations by taxing authorities.
  
 (b) Conveyance Taxes. Purchaser shall be liable for, shall hold Seller and its Affiliates harmless against, and agrees to pay any and all Conveyance Taxes. Purchaser and Seller agree to cooperate in the execution and delivery of all instruments and certificates reasonably necessary to minimize the amount of any Conveyance Taxes and to enable Purchaser and/or Seller to comply with any pre-Closing filing requirements, all at the sole cost and expense of Purchaser.
  
 (c) Tax Deficiencies. Seller shall not permit to exist any Tax deficiencies (including penalties and interest) assessed against or relating to Seller with respect to taxable periods ending on or before, or including, the Closing Date of a character or nature that could reasonably be expected to result in liens or claims on any of the Transferred Assets or on Purchaser’s title or use of the Transferred Assets following the Closing Date or that would reasonably be expected to result in any claim against Purchaser.
  
 (d) Tax Apportionment. Except for Conveyance Taxes (the entirety of which shall be the responsibility of Purchaser), all personal property Taxes, and similar ad valorem obligations levied with respect to the Transferred Assets for a taxable period that includes (but does not end on) the Closing Date (collectively, the “Apportioned Obligations”) shall be apportioned between Seller and Purchaser as of the Closing Date based on the number of days of such taxable period ending on and including the Closing Date (“Pre-Closing Apportioned Period”) and the number of days of such taxable period beginning the day after the Closing Date through the end of such taxable period (the “Post-Closing Apportioned Period”). Seller shall be liable for the proportionate amount of Apportioned Obligations that is attributable to the Pre-Closing Apportioned Period. Purchaser shall be liable for proportionate amount of the Apportioned Obligations that is attributable to the Post-Closing Apportioned Period.
  
 	 
	9
	

	 

  
 7. MISCELLANEOUS PROVISIONS.
  
 7.1 Fees and Expenses. Each party shall bear and pay all fees, costs and expenses that it incurs with respect to this Agreement and the consummation of the Transactions.
  
 7.2 Notices. Any notice or other communication required or permitted to be delivered to any party under this Agreement shall be in writing and shall be deemed properly delivered, given and received: (a) when delivered by hand; (b) on the day sent by e-mail provided that the sender has received confirmation of successful transmission as of or prior to 5:00 p.m. local time of the intended recipient on such day; (c) the first business day after sent by e-mail (to the extent that the sender has received confirmation of successful transmission after 5:00 p.m. local time of the intended recipient on the day sent by e-mail); (d) if sent by registered, certified or first class mail, the third business day after being sent; and (e) if sent by overnight delivery via a national courier service, one business day after being sent, in each case to the address or electronic mail address set forth beneath the name of such party below (or to such other address or e-mail address as such party shall have specified in a written notice given to the other parties hereto): 
  
 if to Purchaser:
  
Gridiron BioNutrients, Inc.
 6991 East Camelback Road, Suite D-300
 Scottsdale, AZ 85251
Attention: Timothy Orr 
Email: tim@gridironmvp.com
  
 with a copy (which shall not constitute notice) to:
       
Meister Seelig & Fein LLP
125 Park Avenue, 7th Floor
New York, NY 10017
Attention: Louis Lombardo
E-mail: LL@msf-law.com
  
 if to Seller:
   
 ST Biosciences, Ltd.
 14 Wall Street, 20th Floor
 New York, NY 10005
 Attention: Jason Frankovich
Email: jfrankovich@stbiosciences.com
  
 with a copy (which shall not constitute notice) to: 
 
Fox Rothschild LLP
 222 South Ninth Street, Suite 2000
 Minneapolis, MN 55402
 Attention: Brett Hanson
Email: bhanson@foxrothschild.com
  
 7.3 Counterparts and Exchanges by Electronic Delivery. This Agreement may be executed in counterparts, each of which shall constitute an original and all of which, when taken together, shall constitute one agreement. The exchange of a fully executed Agreement (in counterparts or otherwise) by electronic delivery in .pdf format shall be sufficient to bind the parties to the terms and conditions of this Agreement.
  
 	 
	10
	

	 

  
 7.4 Governing Law; Venue. This Agreement shall be construed in accordance with, and governed in all respects by, the internal laws of the State of Delaware (without giving effect to principles of conflicts of laws). 
  
 (a) Any legal action or other legal proceeding relating to this Agreement or the Transactions or the enforcement of any provision of this Agreement or the Transactions shall be brought or otherwise commenced in the state courts of the State of Delaware (or, only if the state courts of the State of Delaware decline to accept jurisdiction over a particular matter, in any federal court within the State of Delaware). Each party to this Agreement:
  
 (i) expressly and irrevocably consents and submits to the exclusive jurisdiction and venue of the state courts of the State of Delaware (or, only if the state courts of the State of Delaware decline to accept jurisdiction over a particular matter, in any federal court within the State of Delaware) in connection with any such legal proceeding; 
  
 (ii) agrees that the state courts of the State of Delaware (or, only if the state courts of the State of Delaware decline to accept jurisdiction over a particular matter, the federal courts within the State of Delaware) shall be deemed to be a convenient forum; and
  
 (iii) agrees not to assert (by way of motion, as a defense or otherwise), in any such legal proceeding brought before the state courts of the State of Delaware (or, only if the state courts of the State of Delaware decline to accept jurisdiction over a particular matter, before any federal court within the State of Delaware), any claim that such party is not subject personally to the jurisdiction of such court, that such legal proceeding has been brought in an inconvenient forum, that the venue of such proceeding is improper or that this Agreement or the Transactions or the subject matter of this Agreement or the Transactions may not be enforced in or by such court.
  
 (b) Notwithstanding anything in this Section 7.4, Seller agrees that, if any proceeding is commenced against any Indemnitee by any Person in or before any court or other tribunal anywhere in the world, then such Indemnitee may proceed against Seller in or before such court or other tribunal with respect to any indemnification claim or other claim arising directly or indirectly from or relating directly or indirectly to such proceeding or any of the matters alleged therein or any of the circumstances giving rise thereto. 
  
 (c) EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY AND ANY ACTION, PROCEEDING OR COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT, OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS OR THE ACTIONS OF ANY PARTY HERETO IN NEGOTIATION, ADMINISTRATION, PERFORMANCE OR ENFORCEMENT HEREOF.
  
 7.5 Successors and Assigns; Parties in Interest. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon the parties hereto and their respective successors, assigns, heirs, executors and administrators. 
  
 7.6 No Third Party Beneficiaries. None of the provisions of this Agreement are intended to provide any rights or remedies to any Person other than the parties to this Agreement and their respective successors and assigns (if any). Without limiting the generality of the foregoing, (i) no independent contractor or employee of Seller that is not a party to this Agreement shall have any rights under this Agreement and (ii) no creditor of Seller shall have any rights under this Agreement.
  
 	 
	11
	

	 

  
 7.7 Remedies Cumulative. The rights and remedies of the parties hereto shall be cumulative (and not alternative).
  
 7.8 Amendments. This Agreement may not be amended, modified, altered or supplemented other than by means of a written instrument duly executed and delivered on behalf of the parties hereto.
  
 7.9 Severability. In the event that any provision of this Agreement, or the application of any such provision to any Person or set of circumstances, shall be determined to be invalid, unlawful, void or unenforceable to any extent, the remainder of this Agreement, and the application of such provision to Persons or circumstances other than those as to which it is determined to be invalid, unlawful, void or unenforceable, shall not be impaired or otherwise affected and shall continue to be valid and enforceable to the fullest extent permitted by law.
  
 7.10 Entire Agreement. This Agreement and the Transactional Agreements, including, without limitation, the exhibits and schedules hereto and thereto, set forth the entire understanding of the parties relating to the subject matter thereof and supersede all prior agreements and understandings among or between any of the parties relating to the subject matter thereof, including without limitation the Original APA.
  
 [Remainder of page intentionally left blank]
  
 	 
	12
	

	 

  
 The parties to this Agreement have caused this Agreement to be executed and delivered as of the date first written above.
  
 	 	PURCHASER:
 
GRIDIRON BIONUTRIENTS, INC.	
	 	 	 	 
		By:		
	  
	 Name:
	Timothy Orr 	 
	 	Title:	Chief Executive Officer	 
	 	 	 	 
	  
	 SELLER:
 
ST BIOSCIENCES, LTD.
	  

	  
	  
	  
	  

	  
	 By:
	  
	  

	  
	 Name: 
	 Jason Frankovich 
	  

	  
	 Title: 
	 Chairman
	  

	  
	  
	  
	  

	  
	 JASON FRANKOVICH
	  

	  
	  
	  
	  

	  
	  
	  

	  
	  
	  
	  

	  
	 For purposes of Section 6.2 only:
  
 TIMOTHY ORR
	  

	  
	  
	  
	  

	  
	  
	  

  
 Asset Purchase Agreement Signature Page
  
 	 
	13
	

	 

  
 EXHIBIT A
  
 CERTAIN DEFINITIONS
  
 For purposes of the Agreement (including this Exhibit A):
  
 Affiliate. “Affiliate” shall mean, with respect to any specified Person, any other Person which, directly or indirectly, controls, is under common control with, or is controlled by, such specified Person, through one or more intermediaries or otherwise. For purposes of this definition, the term “control” means the possession, direct or indirect, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of voting securities, by contract or otherwise.
  
 “Business” shall mean the research, development and commercialization of the Product for use in any and all indications.
  
 Consent. “Consent” shall mean any approval, consent, ratification, permission, waiver or authorization (including any authorization from a Governmental Body). 
  
 Contract. “Contract” shall mean any written, oral, implied or other agreement, contract, understanding, arrangement, instrument, note, guaranty, indemnity, representation, warranty, deed, assignment, power of attorney, certificate, purchase order, work order, insurance policy, benefit plan, commitment, covenant, assurance or undertaking of any nature.
  
 Conveyance Taxes. “Conveyance Taxes” shall mean all sales, use, transfer, stamp, stock transfer, recording, registration, documentary, filing, real property transfer and similar Taxes, fees or charges (together with any interest, penalties or additions in respect thereof) imposed by any Governmental Body in respect of the Transferred Assets that become payable in connection with the transactions contemplated by this Agreement.
  
 Elected Amount of Losses. “Elected Amount of Losses” shall have the meaning given to it in Section 5.3.
  
 Employees. “Employees” means the persons employed by Seller for the purposes of or in connection with the Business at Closing (which, at the date of this agreement, consists of those persons named in the list of employees included in Schedule 4.1);
  
 Encumbrance. “Encumbrance” shall mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, equity, trust, equitable interest, claim, preference, right of possession, lease, tenancy, license, encroachment, covenant, infringement, interference, order, proxy, option, right of first refusal, preemptive right, community property interest, legend, defect, impediment, exception, reservation, limitation, impairment, imperfection of title, condition or restriction of any nature (including any restriction on the transfer of any asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).
  
 Governmental Body. “Governmental Body” shall mean any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national organization or body; or (e) individual, entity or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.
  
 	 
	14
	

	 

  
 Indemnity Claim Determination. “Indemnity Claim Determination” shall have the meaning given to it in Section 5.3.
  
 Intellectual Property. “Intellectual Property” shall mean any and all rights in, arising out of, or associated with any of the following in any jurisdiction throughout the world: (a) issued patents and patent applications, as well as any reissues, continuations, divisions, extensions or reexaminations thereof; (b) trademarks, service marks, brands, certification marks, logos, trade dress, trade names, and other similar indicia of source or origin, together with the goodwill connected with the use of and symbolized by, and all registrations, applications for registration, and renewals of, any of the foregoing; (c) copyrights and works of authorship, whether or not copyrightable, and all registrations, applications for registration, and renewals of any of the foregoing; (d) internet domain names and social media account or user names, all associated web addresses, URLs, websites and web pages, and all content and data thereon or relating thereto; (e) trade secrets, know-how, inventions (whether or not patentable), discoveries, improvements, technology, algorithms, apparatus, diagrams, formulae, inventions, business and technical information, databases, data compilations and collections, tools, methods, processes, techniques, and other confidential and proprietary information and all rights therein (f) computer programs, operating systems, applications, firmware, and other code, including all source code, object code, application programming interfaces, data files, databases, protocols, specifications, and other documentation thereof (including without limitation programmers’ notes or logs, source code annotations, user guides, manuals, instructions, software architecture designs, layouts, netlists, development tools, memoranda and records); and (g) all other intellectual or proprietary rights
  
 Intellectual Property Rights. “Intellectual Property Rights” shall mean all past, present, and future rights of the following types, which may exist or be created under the laws of any jurisdiction in the world: (a) rights associated with works of authorship, including exclusive exploitation rights, copyrights, moral rights and mask works; (b) trademark and trade name rights and similar rights; (c) trade secret rights; (d) patent and industrial property rights; (e) other proprietary rights in Intellectual Property; and (f) rights in or relating to registrations, renewals, extensions, combinations, divisions, and reissues of, and applications for, any of the rights referred to in clauses “(a)” through “(e)” above.
  
 Kraws. “Kraws” shall have the meaning given to it in Section 1.4(b).
  
 Liability. “Liability” shall mean any debt, obligation, duty or liability of any nature (including any unknown, undisclosed, unmatured, unaccrued, unasserted, contingent, indirect, conditional, implied, vicarious, derivative, joint, several or secondary liability), regardless of whether such debt, obligation, duty or liability would be required to be disclosed on a balance sheet prepared in accordance with generally accepted accounting principles and regardless of whether such debt, obligation, duty or liability is immediately due and payable.
  
 Losses. “Losses” shall have the meaning given to it in Section 5.2.
  
 Orr. “Orr” shall have the meaning given to it in Section 1.4(b).
  
 Permits. “Permits” shall mean all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Body.
  
 	 
	15
	

	 

  
 Permitted Encumbrance. “Permitted Encumbrance” shall mean the security interest in the Transferred Assets granted by Seller to Ingenius Biotech S.L. pursuant to that certain Amended and Restated Intellectual Property Security Agreement dated October 6, 2021.
  
 Person. “Person” shall mean any individual, partnership limited liability company, corporation, joint venture, trust, or other entity or organization.
  
 Product. “Product” shall mean Mioxal®, the nutraceutical complex composed of essential amino acids, natural coenzymes and minerals.
  
 Product Records. “Product Records” shall mean all books and records, original files, documentation, invoices, purchase orders, notes, development records, purchase records, data or information that have been or are now used in or with respect to, in connection with or otherwise relating to the Product, the active ingredients comprising the Product or the supply or manufacture of the Product, including all correspondence related thereto, whether with any Governmental Body, the counterparties to the Assumed Contracts, any suppliers, manufacturers or otherwise.
  
 Relevant Share Price. “Relevant Share Price” shall mean the lesser of the closing price per share of Purchaser’s common stock, par value $0.001 per share, as quoted on the exchange or quote system upon which such common stock is then listed as of (i) the Closing Date and (ii) the date of the Indemnity Claim Determination.
  
 Salzman IP “Salzman IP” has the meaning given to it on Schedule 4.1 to this Agreement.
  
 TUPE Regulations. "TUPE Regulations" means the Transfer of Undertakings (Protection of Employment) Regulations 2006.
  
 Tangible Property. “Tangible Property” means all computers, equipment, fixtures, office supplies, spare parts and other miscellaneous tangible personal property
  
 Tax. “Tax” shall mean any tax (including any income tax, franchise tax, capital gains tax, estimated tax, gross receipts tax, value‐added tax, surtax, excise tax, ad valorem tax, transfer tax, stamp tax, sales tax, use tax, property tax, business tax, occupation tax, inventory tax, occupancy tax, withholding tax or payroll tax), escheat obligation, levy, assessment, tariff, impost, imposition, toll, duty (including any customs duty), deficiency or fee, and any related charge or amount (including any fine, penalty or interest), that is, has been or may in the future be (a) imposed, assessed or collected by or under the authority of any Governmental Body, or (b) payable pursuant to any tax‐sharing agreement or similar Contract.
  
 Tax Return. “Tax Return” shall mean any return, statement, report, declaration, election, certificate or other document (including estimated Tax returns and reports, withholding Tax returns and reports, any schedule or attachment, and information returns and reports) filed or required to be filed with respect to Taxes.
  
 Transactional Agreements. “Transactional Agreements” shall mean this Agreement, including all exhibits and schedules hereto, and all other documents to be executed and delivered under this Agreement. 
  
 	 
	16
	

	 

  
 Transactions. “Transactions” shall mean (a) the execution and delivery of the Transactional Agreements, and (b) all of the transactions contemplated by the respective Transactional Agreements, including: (i) the sale of the Transferred Assets by Seller to Purchaser in accordance with the Agreement; and (ii) the performance by the parties to the Transactional Agreements of their respective obligations under the Transactional Agreements, and the exercise by the parties to the Transactional Agreements of their respective rights under the Transactional Agreements.
   
 Transferred Assets. “Transferred Assets” shall mean all assets of every kind, nature and description, tangible or intangible, developed, owned or otherwise held by Seller or any officer, employee or consultant of Seller and used or held for use by Seller in the conduct or operations of the Business, including, without limitation, the following: (a) all inventory of Product or Product samples; (b) all Tangible Property related to, or used in connection with, the Business, including, without limitation, all Tangible Property identified on Schedule 2.5; (c) all Intellectual Property and Intellectual Property Rights that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Product, including, without limitation, all Intellectual Property and Intellectual Property Rights identified on Schedule 2.6; (d) all Product Records; (e) all Contracts to which Seller or any of its Affiliates is a party, and rights of Seller or any of its Affiliates, as applicable, under all Contracts, that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business, Product or the Transferred Assets, including, without limitation, all Contracts identified on Schedule 2.7; (f) all transferrable Permits that are used, held for use, necessary or otherwise related to, the conduct of the Business, the Product or the Transferred Assets, including, without limitation, all Permits identified on Schedule 2.8; (g) all telephone numbers, websites, URLs and domain names that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Product; (h) all marketing plans, business plans, operations, pricing, promotions, and business strategies and methods, and promotional and advertising materials (whether or not put into practice) that are used or held for use in connection with, or necessary or otherwise related to, the conduct of the Business or the Product; (i) the goodwill of the Business and the Product including the name “Mioxal” and all derivatives thereof; (j) all rights, claims and causes of action that are now, or at the time of Closing will be, used held for use in connection with or necessary or otherwise related to, the conduct of the Business or any of the Assumed Liabilities; (k) any and all rights to defenses, set-offs and counterclaims against third parties which Seller may have with respect to any of the Transferred Assets (including, without limitation, those against the suppliers or manufactures of the Product or any active ingredient contained therein); (l) all security deposits related to the conduct of the Business or any of the Assumed Liabilities; and (k) all insurance proceed and all rights to insurance proceeds received or receivable in respect of any loss or casualty occurring on or after the Closing with respect to any of the Transferred Assets.
  
 	 
	17
	

	 

  
 EXHIBIT B
  
 FORM OF LOCK-UP / LEAK-OUT AGREEMENT
  
 THIS LOCK-UP/LEAK-OUT AGREEMENT (the “Agreement”) is made and entered into as of this 9th day of November 2021 (the “Effective Date”) by and between Gridiron BioNutrients, Inc., a Nevada corporation (the “Company”), and Jason Frankovich (the “Shareholder”). For all purposes of this Agreement, the term “Shareholder” shall include any and all affiliates (as defined in Rule 405 of the Securities Act of 1933, as amended) and controlling persons of Shareholder and any and all agents, representatives or other persons with whom Shareholder is or may be deemed to be acting in concert in connection with any sales of Common Stock (as defined below) of the Company.
  
 RECITALS:
  
 WHEREAS, the Company, ST BioSciences, Ltd., a company organized under the laws of England and Whales (“STB”), and Shareholder are parties to that certain Amended and Restated Asset Purchase Agreement dated as of November 5, 2021, whereby, among other things, the Company has agreed to acquire from STB all of STB’s right, title and interest in the product Mioxal® and other intellectual property assets associated therewith, in exchange for approximately 70% of the issued and outstanding shares of the Company’s common stock, par value $0.001 per shares (the “Common Stock”), on a post-closing, fully-diluted basis (the “Transaction”); and
  
 WHEREAS, Shareholder is a substantial holder of the ordinary shares of STB and stands to materially benefit from the Transaction; and
  
 WHEREAS, the execution and delivery of this Agreement by Shareholder is a material condition precedent to the consummation of the Transaction by the Company; and 
  
 WHEREAS, it is intended that the shares of Common Stock covered by this Agreement shall include any shares of Common Stock currently owned by the Shareholder; any shares of Common Stock acquired by Shareholder pursuant to the Transactions; and any shares of Common Stock acquired by the Shareholder subsequent to the Effective Date; and
  
 WHEREAS, the Company and the Shareholder understand that the Shareholder’s failure to comply with the terms and conditions of this Agreement could have substantial adverse consequences to the Company, its shareholders and any public trading market for the Common Stock that cannot be reasonably measured or determined at this time;
  
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the parties hereto do hereby agree as follows:
  
 	 
	18
	

	 

  
 1. Subject to compliance with all of the applicable provisions of the United States Securities and Exchange Commission (the “SEC”) Rule 144 as now in effect or hereafter amended, including SEC interpretations thereof, or an effective S-1 Registration Statement filed with the SEC under the Securities Act of 1933, as amended (the “Securities Act”), which is accompanied by a “current” Resale Prospectus that includes shares of Common Stock covered hereby that are sought to be publicly sold by a Shareholder through a registered broker-dealer (respectively, a “Registration Statement” and the “Shareholder Broker”), and except as otherwise expressly provided herein, the Shareholder may only sell the Common Stock subject to the following conditions, commencing on the first anniversary of the Effective Date (the “Lock-Up Period”); provided, however, the Lock-Up Period shall not cover any Common Stock owned by the Shareholder that is included in a Registration Statement, though the provisions of the Leak-Out Period (as defined below) shall continue to be applicable to the Shareholder and the Common Stock. Following the Lock-Up Period, the Shareholder may sell the Common Stock as follows (the “Leak-Out Period”):
  
 1.1 The Shareholder shall be allowed to sell in one (1) week, no more than the greater of (i) five percent (5%) of the total shares of the Company publicly traded on any nationally recognized medium of a stature no less than the Pink OTC Markets, Inc. (the “OTC Pink”) over the previous ten (10) trading days, or (ii) one percent (1%) of the total outstanding shares of the Company as reported in the Company’s most recently filed SEC report or registration statement in the Edgar Archives of the SEC, divided by thirteen (13) weeks, which number may be updated from time to time, based upon the number of shares reflected as being outstanding in the Company’s SEC filings, on a non-cumulative basis, meaning that if the amount of shares allowed to be sold under this subparagraph are not sold in any specific week, that the unsold amount cannot be cumulated and sold in any subsequent week or weeks with the sale of other shares that are allowed to be sold in a specific week. Any sales made by “affiliates” of the Company during the Leak-Out Period are also subject to the standard volume limitations applicable to any “affiliate” of the Company under SEC Rule 144. Notwithstanding, the Company may allow any Shareholder the right to sell or transfer Common Stock in a bona fide private transaction or by gift or for estate planning purposes, subject to receipt of an opinion of legal counsel for the Company that there is an available exemption from registration for any such transaction under the Securities Act, and subject to any transferee’s execution and delivery of a copy of this Agreement; provided, however, in such event, the Shareholder and any transferee in any such conveyance of Common Stock shall be required to aggregate their respective sales of Common Stock during the term of this Agreement so that the combined sale of shares of Common Stock sold by the Shareholder and any transferee does not exceed the number of shares of Common Stock that could have been sold by the Shareholder during the Leak-Out Period as if any such transaction had not occurred; provided, further, however, these provisions of “aggregation” shall not apply to any disposition by operation of law, including the dissolution of an “entity” Shareholder and the distribution of Common Stock to its shareholders or members, pro rata, according to their respective interests in any such entity, or specifically, STB.
  
 1.2 Except as otherwise provided herein (or by operation of law), all Common Stock shall be sold by the Shareholder in “broker’s transactions” and in compliance with the “manner of sale” requirements as those terms are defined in Rule 144 of the SEC during the Leak-Out Period.
  
 	 
	19
	

	 

  
 1.3 An appropriate legend describing this Agreement shall be imprinted on each stock certificate representing Common Stock covered hereby, and the transfer records of the Company’s transfer agent shall reflect such resale restrictions.
  
 2. The delivery of a duly executed copy of this Agreement shall be satisfactory evidence for all purposes of this Agreement that the Shareholder and any broker acting for any Shareholder shall comply with the “brokers’ transactions,” “manner of sale” and limitations on the number of shares of Common Stock that can be sold in any applicable period outlined in Section 1.1 hereof and in compliance with all of the terms and conditions of this Agreement, and no further evidence thereof will be required of the Shareholder; provided, however, the Company shall have the right to confirm such compliance with any Shareholder and any broker acting on behalf of any Shareholder, to the extent that it deems reasonably required or necessary to assure compliance with this Agreement; and provided, however, that the Shareholder can otherwise provide satisfactory evidence to the Company of such compliance, subject to the Company’s acceptance of any such alternative compliance evidence. Failure by the Shareholder or any such broker to provide the Company with reasonable evidence of compliance with the terms and provisions of this Agreement on written request by the Company and within ten (10) business days of such written request shall result in the withdrawal of any legal opinion rendered by legal counsel respecting the lawful sale of the Shareholder’s Common Stock, with advice thereof to the Shareholder and any such broker, and if any of the shares of Common Stock then being sold by the Shareholder are being sold in reliance on a Registration Statement, at the option of the Company, such shares of Common Stock may be withdrawn from the Registration Statement, In any such event, “stop transfer” instructions shall be provided to the Company’s transfer and registrar agent regarding the Shareholder’s Common Stock.
  
 3. Notwithstanding anything to the contrary set forth herein, the Company may, in its sole discretion and in good faith, at any time and from time to time, waive any of the conditions or restrictions contained herein to increase the liquidity of the Common Stock or if such waiver would otherwise be in the best interests of the development of the public trading market for the Company’s Common Stock.
  
 4. In the event of: (a) a completed tender offer to purchase all or substantially all of the Company’s issued and outstanding securities (at least 50.1% or more of the Company’s voting securities); or (b) a merger, consolidation or other reorganization of the Company with or into an unaffiliated entity that results in a change in control of the Company (resulting in a change in control of 50.1% or more of the Company), then this Agreement shall terminate as of the closing of such event, and the Common Stock restrictions on the resale of the Common Stock pursuant hereto shall terminate, though the requirement that all shares of Common Stock shall be subject to sale in accordance will all applicable securities laws, rules and regulations shall continue.
  
 5. The Shareholder shall be entitled to the beneficial rights of ownership of the Common Stock, including the right to vote the Common Stock for any and all purposes.
  
 6. The number of shares of Common Stock included in any allotment that can be sold by the Shareholder hereunder shall be appropriately adjusted should the Company declare and effect a dividend or distribution, undergo a forward split or a reverse split or otherwise reclassify its shares of Common Stock.
  
 	 
	20
	

	 

  
 7. This Agreement may be executed in any number of counterparts with the same force and effect as if all parties had executed the same document.
  
 8. All notices, instructions or other communications required or permitted to be given pursuant to this Agreement shall be given in writing and delivered by certified mail, return receipt requested, overnight delivery or hand-delivered to all parties to this Agreement, to the Company, at 6991 East Camelback Road, Suite D-300, Scottsdale, Arizona 85251 (or the current address of the Company in the SEC Archives as listed in its most recently filed report or registration statement respectively filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or the Securities Act, and to the Shareholder at the Shareholder’s addresses set forth on the signature page to this Agreement. All notices shall be deemed to be given on the same day if delivered by hand or on the following business day if sent by overnight delivery or the second business day following the date of mailing.
  
 9. The resale restrictions on the Common Stock set forth in this Agreement shall be in addition to all other restrictions on transfer imposed by applicable United States and state securities laws, rules and regulations.
  
 10. The Company or the Shareholder who fails to fully adhere to the terms and conditions of this Agreement shall be liable to every other party to this Agreement for any damages suffered by any party by reason of any such breach of the terms and conditions hereof. The Shareholder agrees that in the event of a breach of any of the terms and conditions of this Agreement by the Shareholder, that in addition to all other remedies that may be available in law or in equity to the non-defaulting parties, a preliminary and permanent injunction, without bond or surety, and an order of a court requiring such Shareholder to cease and desist from violating the terms and conditions of this Agreement and specifically requiring the Shareholder to perform his/her/its obligations hereunder is fair and reasonable by reason of the inability of the parties to this Agreement to presently determine the type, extent or amount of damages that the Company or any non-defaulting Shareholder may suffer as a result of any breach of the terms and provisions of this Agreement or the continuation thereof.
  
 11. This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof, and may not be amended except by a written instrument executed by the parties hereto and approved by a majority of the members of the Board of Directors of the Company.
  
 12. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada applicable to contracts entered into and to be performed wholly within said State; and the Company and the Shareholder agree that any action based upon this Agreement may be brought in the United States federal and state courts situated in Nevada only, and that each shall submit to the jurisdiction of such courts for all purposes hereunder.
  
 13. In the event of default hereunder, the non-defaulting parties shall be entitled to recover reasonable attorney’s fees incurred in the enforcement of this Agreement.
  
 14. This Agreement shall be binding upon any successors or assigns of the Common Stock, without qualification.
  
 15. This Agreement shall terminate on the earlier of: (i) the second anniversary of the Effective Date; (ii) the listing on a nationally recognized exchange of no less significance than the New York Stock Exchange or NASDAQ; or (iii) on the completion of any event specified in Section 4 hereof.
  
 	 
	21
	

	 

  
 IN WITNESS WHEREOF, the undersigned have duly executed and delivered this Agreement as of the respective dates indicated below.
  
 	 	 GRIDIRON BIONUTRIENTS, INC.
	
	 	 	 	 
		By:		
	  
	 Name:
	Timothy Orr	 
	 	Title: 	Chief Executive Officer	 
	 	 	 	 
	  
	 JASON FRANKOVICH
	  

	  
	  
	  
	  

	  
	  
	  

	  
	  
	  

	  
	  
	  
	  

	  
	 Address:
	  

	  
	  
	  

	  
	  
	  

  
 	 
	22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]